[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2024 Japan Molecular Diagnostic Analyzers and Reagent Market Shares and Forecasts for 100 Tests: Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing-Supplier Strategies, Emerging Technologies, Latest Instrumentation, Growth Opportunities

May 2020 | 1126 pages | ID: JF974363AB28EN
Venture Planning Group

US$ 3,850.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This new 1,126-page report from LeadingMarketResearch.com contains 56 table.

The report is available by section, and can be customized to specific information needs and budget.The report presents a comprehensive analysis of the Japanese molecular diagnostics market, including:

Major issues pertaining to the Japanese molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.

An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in testing automation and amplification methods.

Five-year test volume and reagent sales forecasts for the following categories:
  • Infectious Diseases
  • Forensic Testing
  • Cancer
  • Paternity Testing/HLA Typing
  • Genetic Diseases
  • Others
Review of testing methodologies an instrumentation technologies.

Feature comparison of automated and semiautomated analyzers.

Sales and market shares of leading suppliers.

Over 60 specific opportunities for molecular diagnostic instruments, test systems, IT and auxiliary products.

Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Business planning issues and concerns.

Contains 1,126 pages and 56 tables
I. INTRODUCTION

II. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Instrumentation
B. Reagent Kits and Test Systems/panels
C. Computers, Software and Automation
D. Auxiliary Products

III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

IV. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets

V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VI. MARKET AND TECHNOLOGY REVIEW

A. DNA Sequencing
  1. Introduction
  2. Sequencing Methods
  3. Autoradiography
  4. The Human Genome Project
  5. Sequencing Automation
  6. Image Scanners
  7. Fluorescent Detection
  8. Gene Profiling
  9. Gene Expression
  10. Polymorphism Screening
  11. Protein Interaction Networks
B. DNA and RNA Probe Technologies
  1. Basic Principles
  2. Probe Preparation
  3. The DNA Probe Test
  4. Test Formats
  5. Labeling Techniques
  6. Amplification Methods
C. Detection Technologies
  1. Radioactive Methods
  2. Non-Isotopic Methods
D. Instrumentation
Review of latest analyzers from Abbott, Beckman Coulter/Danaher, ??? Becton Dickinson, bioMerieux, Bio-Rad, Cepheid, Hologic, Qiagen, Roche, ?†?Siemens Healthineers, and others.
E. Biochips: Genosensors, Microarrays, and Labs-on-the-Chip
F. Pharmacogenomics
G. Major Applications
  1. Microbiology/Infectious Diseases
    a. Overview
    b. Major Infectious Diseases
      AIDS: HIV/HIV-1/2/Combo, HIVAg/HIV NAT, Western Blot, HTLV-I/II
      Adenovirus
      Aeromonas
      Anthrax/Bacillus Anthracis
      Arboviruses
      Babesiosis
      Bacillary Epithelioid Angiomatosis (BEA) and Other Bartonella (Rochalimaea)
      Blastocystis Hominis
      Brucella
      Campylobacter
      Candida
      Chagas Disease
      Chancroid
      Chlamydia
      Clostridium Difficile
      Coronaviruses
      Coxsackieviruses
      Creutzfeldt-Jakob’s Disease
      Cryptosporidium Parvum
      Cyclospora Cayetanensis
      Cytomegalovirus
      Ebola Virus
      E. Coli
      EchoVirus
      Encephalitis
      Enteroviruses
      Epstein-Barr Virus
      Giardia Lamblia
      Gonorrhea
      Granuloma Inguinale
      Hantavirus
      Helicobacter Pylori
      Hepatitis: HAV NAT, HBV NAT, HBs Ag, HCV, HCV NAT, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, ALT/SGPT
      Herpes Simplex Virus
      Human Herpes Virus-6 (HHV-6)
      Influenza Viruses
      Legionella
      Lyme Disease
      Lymphogranuloma Venereum (LGV)
      Malaria
      Measles (Rubeola)
      Meningitis
      Microsporidium
      Mononucleosis
      Mumps
      Mycoplasma
      Papillomaviruses
      Parvovirus B19
      Pneumonia
      Polyomaviruses
      Pseudomonas Aeruginosa
      Rabies
      Respiratory Syncytial Virus (RSV)
      Rhinoviruses
      Rotavirus
      Rubella
      Salmonellosis
      Septicemia
      Shigellosis
      Staphylococcus Aureus
      Streptococci
      Syphilis
      Toxoplasmosis
      Trichomonas Vaginalis
      Tuberculosis
      Vibrio
      West Nile Virus
      Yersina
  2. Cancer Testing
    a. Overview
    b. Major Cancer Types
      Prostate
      Lung
      Colon and Rectum
      Breast
      Skin
      Uterine
      Leukemia
      Oral
    c. Oncogenes
The report provides review of both current and emerging oncogenes, including:
  Abl/abl-bcr
  AIB1
  BCL-2
  BRCA1
  CD44
  C-fos
  C-myb
  C-myc
  CYP17
  Erb-B
  HPC1
  N-myc
  P40
  P51
  P53
  PIK3CA
  PTI-1
  Ras
  Reg
  Sis
  Src
  3. Genetic Diseases
    a. Overview
    b. Nucleic Acid Amplification
    c. Chromosome Imaging
    d. Genomics Technologies
    e. Proteomics Technologies
    f. Current Pharmacogenomic Tests
    g. Future Pharmacogenomic Testing
    h. Major Diseases
      Achondroplasia
      Autosomal Dominant Polycystic Kidney Disease
      Cancer
      Cosmetogenomics
      Cystic Fibrosis
      Down's Syndrome
      Duchenne and Becker Muscular Dystrophy
      Factor V (Leiden)
      Factor IX Deficiency
      Fragile X Syndrome
      Heart Disease
      Hemochomatosis
      Hemophilia
      Huntington's Disease
      Maternal-Fetal Incompatibility
      Multiple Endocrine Neoplasia
      Phenylketonuria (PKU)
      Polycystic Kidney Disease (PKD)
      Prenatal Screening
      Retinitis Pigmentosa
      Retinoblastoma
      Sickle Cell Anemia
      Spinal Muscular Atrophy
      Vitamin B12 Metabolism
    i. Social Issues and Concerns
  4. Forensic Testing
    a. Overview
    b. Multilocus and Single Locus Probes
    c. The FBI
    d. DNA Profile Data Banks
    e. Judicial Implementation
    f. Major Crime Categories
    g. Factors Contributing to the DNA Probe
Market Expansion
    h. Wildlife Forensics
  5. Paternity Testing/HLA Typing
  6. Other Applications
    a. Disease Susceptibility Testing
    b. Cardiovascular Diseases
    c. Diabetes
    d. Alzheimer's Disease
    e. Periodontal Disease
    f. Plasma Purification
    g. Organ Transplantation
    h. W ater Contamination
    i. Other
H. Competing/Complementing Technologies
  1. Monoclonal Antibodies/Immunoassays
  2. RNA Probes
  3. Two-Dimensional Electrophoresis
  4. Flow Cytometry

VII. MOLECULAR DIAGNOSTICS MARKET

A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Test Volume and Sales Forecasts, Major Supplier Sales and Market Shares

VIII. COMPETITIVE ASSESSMENTS

The report provides strategic assessments of over 40 leading molecular diagnostics market players and start-up companies with innovative technologies and products, including: Abbott, Agilent Technologies, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, Cepheid, DiaSorin, Eiken Chemical, Enzo, Fujirebio, Grifols, Hologic, Illumina, LabCorp/Sequenom, Leica Biosystems, Myriad Genetics, OrthoClinical Diagnostics, Qiagen, Quest Diagnostics, Quidel, Roche, Shimadzu, Siemens Healthineers, Sierra Molecular, Takara Bio, Tecan Group, Thermo Fisher, Wako and others.

LIST OF TABLES

Major Companies Developing or Marketing AIDS Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Adenovirus Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Bartonella Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Campylobacter Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Candida Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Chlamydia Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Clostridium Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Coronavirus Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Cryptosporidium Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing CMV Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Echovirus Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Enterovirus Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing EBV Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Giardia Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Gonorrhea Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Hantavirus Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Helicobacter Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Hepatitis Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Herpes Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Influenza Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Legionella Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Lyme Disease Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Measles Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Meningitis Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Mononucleosis Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Mumps Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Mycoplasma Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Pneumonia Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing RSV Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Rotavirus Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Rubella Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Salmonella Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Septicemia Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Shigella Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Streptococci Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Syphilis Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Toxoplasmosis Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Trichomonas Molecular Diagnostic and Other Direct Identification Tests
Major Companies Developing or Marketing Tuberculosis Molecular Diagnostic and Other Direct Identification Tests
Oncogenes Potential Application in Cancer Diagnosis
Major Companies Developing or Marketing Cancer Molecular Diagnostic Tests
Major Companies Developing or Marketing Molecular Diagnostic Tests For Genetic Diseases
Japan
Molecular Diagnostics Test Volume And Sales By Major Application
Japan
Laboratories Performing DNA Sequencing By Market Segment
Japan
Molecular Diagnostics Market Potential Laboratory Universe by Market Segment
Japan
Molecular Diagnostics Test Volume By Major Application
Japan
Major Infectious Disease Test Volume by Assay
Japan
Major Infectious Disease Test Volume by Method
Japan
Molecular Diagnostics Market By Major Application
Japan
Molecular Diagnostics Market Estimated Sales And Market Shares of Major Suppliers
Japan
Major Infectious Disease Diagnostics Market by Assay
Japan
AIDS Testing Market Estimated Sales by Major Supplier
Japan
Chlamydia Testing Market Estimated Sales by Major Supplier
Japan
CMV Testing Market Estimated Sales by Major Supplier
Japan
Gonorrhea Testing Market Estimated Sales by Major Supplier
Japan
Hepatitis Testing Market Estimated Sales by Major Supplier
Japan
Hepatitis C Testing Market Estimated Sales by Major Supplier
Japan
Herpes Testing Market Estimated Sales by Major Supplier
Japan
Meningitis Testing Market Estimated Sales by Major Supplier
Japan
Mycoplasma Testing Market Estimated Sales by Major Supplier
Japan
Pneumonia Testing Market Estimated Sales by Major Supplier
Japan
Shigella Testing Market Estimated Sales by Major Supplier


More Publications